- Home
- TR vs DNLI Comparison
TR vs DNLI Comparison
Compare TR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TR
- DNLI
- Stock Information
- Founded
- TR 1896
- DNLI 2013
- Country
- TR United States
- DNLI United States
- Employees
- TR N/A
- DNLI N/A
- Industry
- TR Specialty Foods
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TR Consumer Staples
- DNLI Health Care
- Exchange
- TR Nasdaq
- DNLI Nasdaq
- Market Cap
- TR 2.9B
- DNLI 2.3B
- IPO Year
- TR N/A
- DNLI 2017
- Fundamental
- Price
- TR $42.87
- DNLI $15.54
- Analyst Decision
- TR
- DNLI Strong Buy
- Analyst Count
- TR 0
- DNLI 15
- Target Price
- TR N/A
- DNLI $33.50
- AVG Volume (30 Days)
- TR 212.9K
- DNLI 2.0M
- Earning Date
- TR 10-27-2025
- DNLI 11-05-2025
- Dividend Yield
- TR 0.85%
- DNLI N/A
- EPS Growth
- TR N/A
- DNLI N/A
- EPS
- TR 1.24
- DNLI N/A
- Revenue
- TR $722,849,000.00
- DNLI N/A
- Revenue This Year
- TR N/A
- DNLI N/A
- Revenue Next Year
- TR N/A
- DNLI $95,463.19
- P/E Ratio
- TR $33.68
- DNLI N/A
- Revenue Growth
- TR N/A
- DNLI N/A
- 52 Week Low
- TR $28.32
- DNLI $10.57
- 52 Week High
- TR $43.97
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- TR 61.26
- DNLI 57.15
- Support Level
- TR $41.55
- DNLI $14.02
- Resistance Level
- TR $43.68
- DNLI $16.51
- Average True Range (ATR)
- TR 0.98
- DNLI 0.79
- MACD
- TR -0.08
- DNLI 0.09
- Stochastic Oscillator
- TR 68.79
- DNLI 67.60
About TR Tootsie Roll Industries Inc.
Tootsie Roll Industries Inc manufactures and sells confectionery products. Notable varieties include Tootsie Roll and Tootsie Pops, Charms, Blow-Pops, Dots, Junior Mints, Sugar Daddy and Sugar Babies, Andes, Dubble Bubble, Razzles among others. The company sells its products to wholesale distributors and directly to retail stores. Geographically, it generates a majority of its revenue from the United States and rest from Canada, Mexico and other regions.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.